- Home
- BMGL vs GALT Comparison
BMGL vs GALT Comparison
Compare BMGL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- GALT
- Stock Information
- Founded
- BMGL 2001
- GALT 2000
- Country
- BMGL Singapore
- GALT United States
- Employees
- BMGL N/A
- GALT N/A
- Industry
- BMGL
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- BMGL
- GALT Health Care
- Exchange
- BMGL NYSE
- GALT Nasdaq
- Market Cap
- BMGL 78.3M
- GALT 83.5M
- IPO Year
- BMGL 2025
- GALT N/A
- Fundamental
- Price
- BMGL $6.08
- GALT $1.31
- Analyst Decision
- BMGL
- GALT Hold
- Analyst Count
- BMGL 0
- GALT 1
- Target Price
- BMGL N/A
- GALT N/A
- AVG Volume (30 Days)
- BMGL 11.2M
- GALT 176.3K
- Earning Date
- BMGL 01-01-0001
- GALT 05-15-2025
- Dividend Yield
- BMGL N/A
- GALT N/A
- EPS Growth
- BMGL 16.23
- GALT N/A
- EPS
- BMGL 0.09
- GALT N/A
- Revenue
- BMGL $7,428,776.00
- GALT N/A
- Revenue This Year
- BMGL N/A
- GALT N/A
- Revenue Next Year
- BMGL N/A
- GALT N/A
- P/E Ratio
- BMGL $64.62
- GALT N/A
- Revenue Growth
- BMGL 3.32
- GALT N/A
- 52 Week Low
- BMGL $0.91
- GALT $0.73
- 52 Week High
- BMGL $7.18
- GALT $3.17
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- GALT 48.59
- Support Level
- BMGL N/A
- GALT $1.22
- Resistance Level
- BMGL N/A
- GALT $1.36
- Average True Range (ATR)
- BMGL 0.00
- GALT 0.10
- MACD
- BMGL 0.00
- GALT -0.00
- Stochastic Oscillator
- BMGL 0.00
- GALT 29.41
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.